Education and Training
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
This is a study to evaluate the safety and effectiveness of ADX-N05 compared to placebo in the treatment of excessive daytime sleepiness in adults with narcolepsy.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: ADX-N05
- drug: Placebo
Eligibility
Inclusion Criteria:
- Diagnosis of narcolepsy
- Good general health
- Willing and able to comply with the study design and schedule and other requirements
Exclusion Criteria:
- If female, pregnant or lactating
- Customary bedtime later than midnight
- History of significant medical condition, behavioral, or psychiatric disorder
(including suicidal ideation), or surgical history
- Any other clinically relevant medical, behavioral or psychiatric disorder other than
narcolepsy that is associated with excessive sleepiness
- History of significant cardiovascular disease
- Body mass index > 34
- Excessive caffeine use - > 600 mg/day of caffeine or > 6 cups of coffee/day
- History of alcohol or drug abuse within the past 2 years
- Nicotine dependence that has an effect on sleep
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Paul Stowers
650-721-7551
I'm interested